Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647971 · ClinicalTrials.gov registry record · Phase 1
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma and Marginal Zone Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 8
- Study locations
NCT01647971 is a Phase 1 study of Non-Hodgkin's Lymphoma and Marginal Zone Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 39 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT01647971, a Phase 1 study of Non-Hodgkin's Lymphoma and Marginal Zone Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Conditions Studied
Interventions
- DRUG Ublituximab
Study Locations (8)
Georgia
- TG Therapeutics Investigational Trial Site - Athens
- TG Therapeutics Investigational Trial Site - Macon
Alabama
- TG Therapeutics Investigational Trial Site - Huntsville
Arkansas
- TG Therapeutics Investigational Trial Site - Jonesboro
Maryland
- TG Therapeutics Investigational Trial Site - Bethesda
New Jersey
- TG Therapeutics Investigational Trial Site - Morristown
New York
- TG Therapeutics Investigational Trial Site - New York
Tennessee
- TG Therapeutics Investigational Trial Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-07-19 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647971
The ClinicalTrials.gov registry entry for NCT01647971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (82% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT01647971 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Georgia, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01647971 about?
NCT01647971 is a clinical study titled "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
What is the current status of trial NCT01647971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2012-07-19. Estimated completion is 2015-05.
What conditions does trial NCT01647971 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT01647971?
The interventions under investigation include: Ublituximab (DRUG).
Who is sponsoring clinical trial NCT01647971?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01647971 being conducted?
This trial has 8 study locations across Alabama, Arkansas, Georgia, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.